Rosetta Genomics Looking Beyond Cancer to Cardio, Neuro, Women's Health for Blood-Based MDx Program | GenomeWeb

Testing patient blood samples for diagnostic or prognostic microRNA markers is the "next big thing" for Rosetta Genomics.

CEO Ken Berlin said last week that the company is developing a number of tests that can be performed on bodily fluids from patients. Should Rosetta successfully commercialize these tests, the Rehovot, Israel-based molecular diagnostics firm believes it could address other lucrative markets.

The company already offers a menu of oncology tests that are performed on biopsy samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.